Scientists Find a Gut-Healing Drug That Reverses Deadly Liver Disease

A Liver Disease Treated Through the Gut

Scientists at the University of Michigan have developed a promising drug candidate that reversed a severe form of fatty liver disease in animal studies by targeting an unexpected source: the gut. It's a counterintuitive approach — treating the liver by fixing the intestines — but the results are turning heads in the medical community and raising real hope for millions of people who have few good options today.

The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage. MASH is the most severe form of fatty liver disease and can progress to cirrhosis, liver failure, and liver cancer.

How Bad Gut Bacteria Wreck the Liver

Chen's research team had previously demonstrated that DT-109, a glycine-based tripeptide — a small molecule made from three amino acids, which are the building blocks of proteins — could improve MASH in animal studies. What remained unclear was exactly how the compound produced its protective effects. The latest research provides an explanation, revealing how changes in gut bacteria can set off a chain reaction that damages the liver and how DT-109 can interrupt that process.

Before examining the drug's effects, the scientists confirmed an important contributor to MASH: excessive growth of Clostridium perfringens, a bacterium that produces ammonia inside the intestines. In experiments involving mice and non-human primates, DT-109 reduced C. perfringens levels, lowered intestinal ammonia production, and repaired the gut barrier. By preventing harmful microbial products from entering the bloodstream, the drug reduced liver inflammation and significantly improved MASH.

Promising Results in Animals Close to Humans

The benefits were particularly encouraging in non-human primates, whose gut microbiome and liver biology closely resemble those of humans, suggesting the findings may have greater relevance for future clinical research. That distinction matters. Results in mice alone often fail to translate to people, so seeing the same effects in primates adds a meaningful layer of confidence to the science.

According to Eugene Chen, M.D., Ph.D., senior author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School, "We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression."

A Drug That Could Do Even More

Researchers also believe DT-109 could have broader health benefits. Previous studies suggest it may reduce the development of atherosclerosis and vascular calcification, while the restoration of gut barrier function could make it a potential therapy for conditions such as inflammatory bowel disease (IBD). That's a remarkable range of potential applications for a single compound.

The findings are currently limited to animal studies, and the drug has not yet been tested in people. The research team aims to pursue clinical trials to further evaluate the compound's potential. If those trials go forward and DT-109 proves safe and effective in humans, it could represent a fundamental shift in how doctors think about — and treat — liver disease, addressing the problem not where it shows up, but where it actually starts.